At a glance
ClinicalIndex Comparison RecordN/ACompleted· 73,989 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SAFETY AND EFFECTIVENESS EVALUATION OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION TREATED WITH OACS: COMPARISON BETWEEN NOACS AND WARFARIN (CER3)
In Brief
An observational study for Non-valvular Atrial Fibrillation. Completed, enrolled 73,989 participants across 1 site.
Detailed Summary
An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of thromboembolism and it had long been the only oral anticoagulant until the first non-vitamin K antagonist oral anticoagulants (NOACs). However, its safety and effectiveness remains unknown in real-world clinical practice in Japan
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-valvular Atrial Fibrillation
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJun 2018
Primary CompletionOct 2018
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartMay 8, 2018
Primary CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.0 years ago